Boehringer Ingelheim's Gilotrif is approved for those with advanced squamous cell lung cancer (SqCC) that has progressed despite treatment with platinum-based chemotherapy.
Gilotrif was already approved for those who have non-small cell lung cancer (NSCLC) with a certain type of epidermal growth factor receptor (EGFR) mutation.
Gilotrif's recent approval offers a new treatment option for a disease that is typically associated with a poor prognosis.
In a clinical trial, Gilotrif demonstrated a delay in the progression of lung cancer, an improvement in overall survival and an improvement in the control rate of lung cancer, according to a company-issued press release.
Common side effects reported with Gilotrif were diarrhea, rash or acne, mouth sores, decreased appetite and nausea.